Vaccine safety

Immunology and Allergy Clinics of North America

Volumn 23, Issue 4, 2003, Pages 589-603

  Jacobson, Robert M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; EGG PROTEIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; LYME DISEASE VACCINE; MEASLES MUMPS RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE; PLACEBO; ROTAVIRUS VACCINE; TETANUS TOXOID; THIOMERSAL; VACCINE;

ANAPHYLAXIS; ANOREXIA; ARTHRALGIA; ARTHRITIS; ATAXIA; AUTISM; BRAIN DISEASE; CHICKENPOX; CLINICAL TRIAL; COLLAPSE; CONGENITAL RUBELLA SYNDROME; CONJUNCTIVITIS; CONVULSION; CROHN DISEASE; CRYING; DEVELOPMENTAL DISORDER; DIARRHEA; DISABILITY; DROWSINESS; DRUG APPROVAL; DRUG FATALITY; DRUG SAFETY; EDEMA; FEBRILE CONVULSION; FEVER; FLU LIKE SYNDROME; FOREIGN BODY; GUILLAIN BARRE SYNDROME; HERPES ZOSTER; HOSPITALIZATION; HUMAN; HYPERSENSITIVITY; IMMUNIZATION; INJECTION PAIN; INTUSSUSCEPTION; IRRITABILITY; MALAISE; METABOLIC DISORDER; MULTIPLE SCLEROSIS; MUSCLE HYPOTONIA; MYALGIA; NEURITIS; NEUROLOGIC DISEASE; OPHTHALMOPLEGIA; OPTIC NERVE DISEASE; OTITIS MEDIA; PAIN; POLIOMYELITIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RASH; REVIEW; SHOCK; SIDE EFFECT; SKIN INDURATION; THROMBOCYTOPENIA; ULCERATIVE COLITIS; VASCULITIS; VOMITING;

EID: 0347363624     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8561(03)00090-0     Document Type: Review

References (69)

1. Centers for Disease Control and Prevention. Achievements in public health, 1990-1999. Impact of vaccines universally recommended for children-United States, 1990-1998. MMWR Morb Mortal Wkly Rep 1999;48:243-8.
2. Centers for Disease Control and Prevention. Ten great public health achievements-United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999;48:241-3.
3. Hanratty B, Holt T, Duffell E, Patterson W, Ramsay M, White JM, et al. UK measles outbreak in non-immune anthroposophic communities: the implications for the elimination of measles from Europe. Epidemiol Infect 2000;125:377-83.
4. van den Hof S, Meffre CM, Conyn-van Spaendonck MA, Woonink F, de Melker HE, van Binnendijk RS. Measles outbreak in a community with very low vaccine coverage, the Netherlands. Emerging Infect Dis 2001;7:593-7.
5. Mitchell P. Public-health threat of measles-vaccine refusal spelled out. Lancet 1999;354:133.
6. Salmon DA, Haber M, Gangarosa EJ, Phillips L, Smith NJ, Chen RT. Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles. JAMA 1999;282:47-53.
7. Feikin DR, Lezotte DC, Hamman RF, Salmon DA, Chen RT, Hoffman RE. Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA 2000;284:3145-50.
8. Coughlan S, Connell J, Cohen B, Jin L, Hall WW. Suboptimal measles-mumps-rubella vaccination coverage facilitates an imported measles outbreak in Ireland. Clin Infect Dis 2002;35:84-6.
9. Reaney EA, Tohani VK, Devine MJ, Smithson RD, Smyth B. Mumps outbreak among young people in Northern Ireland. Commun Dis Public Health 2001;4:311-5.
10. Institute of Medicine. Vaccine supply and innovation. Washington, DC: National Academy Press; 1985.
11. Chen RT, Hibbs B. Vaccine safety: current and future challenges. Pediatr Ann 1998;27:445-55.
12. Zhou W, Pool V, lskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR Morb Mortal Wkly Rep 2003;52:1-24.
13. Institute of Medicine. Adverse events associated with childhood vaccines: evidence bearing on causality. Washington, DC: National Academy Press; 1994.
14. Bridges CB, Harper SA, Fukuda K, Uyeki TM, Cox NJ, Singleton JA. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2003;52:1-36.
15. American Lung Association Asthma Clinical Research Centers. Safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med 2001;345:1529-36.
16. Lasky T, Terracciano GJ, Magder L. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-802.
17. Immunization Practices Advisory Committee. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 1991;40:1-19.
18. Stratton K, Almario DA, McCormick MC, Immunization Safety Review Committee, Board of Health Promotion and Disease Prevention, Institute of Medicine. Immunization safety review: hepatitis B Vaccine and demyelinating neurological disorders. Washington, DC: National Academy Press; 2002.
19. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 1991;40:1-28.
20. Baraff LJ, Shields WD, Beckwith L, Strome G, Marcy SM, Cherry JD, et al. Infants and children with convulsions and hypotonic-hyporesponsive episodes following diphtheria-tetanus-pertussis immunization: follow-up evaluation. Pediatrics 1988;81:789-94.
21. Hirtz DG, Nelson KB, Ellenberg JH. Seizures following childhood immunizations. J Pediatr 1983;102:14-8.
22. Long SS, Deforest A, Smith DG, Lazaro C, Wassilak GF. Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy. Pediatrics 1990;85:294-302.
23. Evans G. Vaccine liability and safety revisited. Arch Pediatr Adolesc Med 1998;152:7-10.
24. Cody C, Baraff L, Cherry J, Marcy S, Manclark C. The nature and rate of adverse reactions associated with DTP and DT immunization in infants and children. Pediatrics 1981;68:650-60.
25. Barlow WE, Davis RL, Glasser JW, Rhodes PH, Thompson RS, Mullooly JP, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001;345:656-61.
26. Centers for Disease Control and Prevention. Notice to readers: Food and Drug Administration approval of a fifth acellular pertussis vaccine for use among infants and young children-United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:574.
27. Institute of Medicine. Adverse effects of pertussis and rubella vaccines. Washington, DC: National Academy Press; 1991.
28. Dittmann S. Vaccine safety: risk communication-a global perspective. Vaccine 2001;19:2446-56.
29. Piyasirisilp S, Hemachudha T. Neurological adverse events associated with vaccination. Curr Opin Neurol 2002;15:333-8.
30. Centers for Disease Control and Prevention. Notice to readers: FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined (PEDIARIX®) for use in infants. MMWR Morb Mortal Wkly Rep 2003;52:203-4.
31. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000;49:1-22.
32. Stratton K, Almario DA, McCormick MC. Immunization Safety Review Committee, Board of Health Promotion and Disease Prevention, Institute of Medicine. Immunization safety review: SV40 contamination of polio vaccine and cancer. Washington, DC: National Academy Press; 2002.
33. Centers for Disease Control and Prevention. Haemophilus b: conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older: recommendations of the ACIP. MMWR Morb Mortal Wkly Rep 1991;40:1-7.
34. Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999;48:1007.
35. Dennehy PH, Bresee JS. Rotavirus vaccine and intussusception: where do we go from here? Infect Dis Clin North Am 2001;15:189-207.
36. Clements-Mann ML, Dudas R, Hoshino Y, Nehring P, Sperber E, Wagner M, et al. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. Vaccine 2001;19:4676-84.
37. Georges AM. Regulatory aspects of clinical trials with vaccines. Dev Biol Stand 1998;95:69-74.
38. Hessel L. Developing vaccines involving new technologies to ensure safety and timely licensure: the industry perspective. Vaccine 2001;20:S70-2.
39. Murphy BR, Morens DM, Simonsen L, Chanock RM, La Montagne JR, Kapikian AZ. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. J Infect Dis 2003;187:1301-8.
40. Centers for Disease Control and Prevention. Prevention of varicella-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996;45:1-25.
41. Centers for Disease Control and Prevention. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, mumps, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998;47:1-57.
42. Institute of Medicine. Evidence concerning rubella vaccines and arthritis, radiculoneuritis, and thrombocytopenic purpura. In: Howson CP, Howe CJ, Fineberg HV, editors. Adverse effects of pertussis and rubella vaccines. Washington, DC: National Academy Press; 1991. p. 187-205.
43. Institute of Medicine. Measles and mumps vaccines. In: Stratton KR, Howe CJ, Johnston RB, editors. Adverse events associated with childhood vaccines. Washington, DC: National Academy Press; 1994. p. 118-86.
44. Wakefield AJ, Pittilo RM, Sim R, Cosby SL, Stephenson JR, Dhillon AP, et al. Evidence of persistent measles virus infection in Crohn's disease. J Med Virol 1993;39:345-53.
45. Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ. Is measles vaccination a risk factor for inflammatory bowel disease? Lancet 1995;345:1071-4.
46. Wakefield AJ, Murch SH, Linnell AA, Casson DM, Malik M, Berelowitz M, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637-41.
47. Nicoll A, Elliman D, Ross E. MMR vaccination and autism. BMJ 1998;316:715-6.
48. Noble KK, Miyasaka K. Measles, mumps, and rubella vaccination and autism. N Engl J Med 2003;348:951-4.
49. Taylor B, Miller E, Farrington CP, Petropoulos MC, Favot-Mayaud I, Li J, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999;353:2026-9.
50. Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, et al. MMR vaccination and autism-a population-based follow-up study. Ugeskr Laeger 2002;164:5741-4.
51. Dales L, Hammer SJ, Smith NJ. Time trends in autism and in MMR immunization coverage in California. JAMA 2001;285:1183-5.
52. Peltola H, Patja A, Leinikki P, Valle M, Davidkin I, Paunio M. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. Lancet 1998;351:1327-8.
53. Stratton K, Gable A, Shetty P, McCormick M, et al. Immunization Safety Review Committee, Board of Health Promotion and Disease Prevention. Immunization safety review: measles-mumps-rubella vaccine and autism. Washington, DC: National Academy Press; 2001.
54. Morris DL, Montgomery SM, Thompson NP, Ebrahim S, Pounder RE, Wakefield AJ. Measles vaccination and inflammatory bowel disease: a national British cohort study. Am J Gastroenterol 2000;95:3507-12.
55. Feeney M, Ciegg A, Winwood P, Snook J. A case-control study of measles vaccination and inflammatory bowel disease: the East Dorset Gastroenterology Group. Lancet 1997;350:764-6.
56. Pebody RG, Paunio M, Ruutu P. Measles, measles vaccination, and Crohn's disease: Crohn's disease has not increased in Finland. BMJ 1998;316:1745-6.
57. Centers for Disease Control and Prevention. Notice to readers: revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR Morb Mortal Wkly Rep 2001;50:1117.
58. Advisory Committee on Immunization Practices. Recommendations for use of Lyme disease vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999;48:1-17.
59. SmithKline Beecham. Prescribing Information: LYMErix® Lyme Disease vaccine (Recombinant OspA). Rixensart, Belgium: SmithKline Beecham Biologicals; 2001. p. 3.
60. Rahn DW. Lyme vaccine: issues and controversies. Infect Dis Clin North Am 2001;15:171-87.
61. Gellin BG, Maibach EW, Marcuse EK. Do parents understand immunizations? A national telephone survey. Pediatrics 2000;106:1097-102.
62. Offit PA, Hackett CJ. Addressing parents' concerns: do vaccines cause allergic or autoimmune diseases? Pediatrics 2003;111:653-9.
63. Offit PA, Quarles J, Gerber MA, Hackett CJ, Marcuse EK, Kollman TR, et al. Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system? Pediatrics 2002;109:124-9.
64. Centers for Disease Control and Prevention. Notice to readers: thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR Morb Mortal Wkly Rep 1999;48:563-5.
65. Centers for Disease Control and Prevention. Recommendations regarding the use of vaccines that contain thimerosal as a preservative. MMWR Morb Mortal Wkly Rep 1999;48:996-8.
66. Ellenberg SS, Braun MM. Monitoring the safety of vaccines: assessing the risks. Drug Saf 2002;25:145-52.
67. Jacobson RM, Adegbenro A, Pankratz VS, Poland GA. Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study. Vaccine 2001;19:2428-33.
68. Chen RT, Rastogi SC, Mullen JR. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 1994;12:542-50.
69. Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States: the Vaccine Safety Datalink Team. Pediatrics 1997;99:765-73.